|
Market Closed -
London S.E.
11:35:27 2026-08-27 am EDT
|
5-day change | 1st Jan Change | ||
| 1,852.00 GBX | -2.50% |
|
-3.34% | +1.51% |
| 12:02pm | FTSE down as inflation fear offsets Nvidia lift | AN |
| 11:19am | European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading | MT |
| Market Cap | 76.11B 103B 88.78B 83.12B 143B 9,878B 144B 984B 385B 4,979B 388B 380B 16,477B | P/E 2026 * |
14.4x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 95.95B 130B 112B 105B 181B 12,453B 181B 1,241B 485B 6,276B 490B 479B 20,772B | EV / Sales 2026 * |
2.83x | EV / Sales 2027 * | 2.62x |
| Free-Float |
92.75% | Yield 2026 * |
3.66% | Yield 2027 * | 3.95% |
Last Transcript : GSK plc
| Aug. 25 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 20 | Cancer vaccines finally garner the spotlight |  |
| Aug. 19 | GSK plc : Deutsche Bank remains Neutral | ZD |
| Aug. 17 | GSK Kept at Hold as Berenberg Notes Cost Savings Plan | MT |
| Aug. 17 | GSK plc : Berenberg gives a Neutral rating | ZD |
| 1 day | -3.21% | ||
| 1 week | -3.34% | ||
| Current month | -4.12% | ||
| 1 month | -5.56% | ||
| 3 months | -3.79% | ||
| 6 months | -14.54% | ||
| Current year | +1.51% |
| 1 week | 1,852 |  | 1,937 |
| 1 month | 1,803 | | 2,096 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,440.29 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/29/26 | Sell | Executive/Senior Manager | -38,000 | 0.0009% | ||
| 7/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 7/14/26 | Buy | Chief Technology Officer | 660 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.50% | -3.34% | +26.03% | +32.49% | 103B | |
| -1.25% | -5.74% | +59.77% | +111.76% | 1,060B | |
| -1.55% | -0.70% | +50.17% | +61.60% | 651B | |
| -1.85% | -1.65% | +23.77% | +74.67% | 465B | |
| -1.17% | -2.10% | +38.61% | +40.46% | 365B | |
| -2.00% | -1.35% | +22.22% | +37.78% | 300B | |
| -0.98% | +0.53% | +2.04% | +12.13% | 258B | |
| -0.68% | +0.89% | +51.95% | +70.56% | 238B | |
| -3.18% | -0.30% | -17.23% | -54.33% | 210B | |
| +0.29% | +3.39% | +30.18% | +92.50% | 184B | |
| Average | -1.48% | -0.68% | +28.75% | +47.96% | 383.39B | |
| Weighted average by Cap. | -1.40% | -2.12% | +37.91% | +64.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.94B 46.12B 39.59B 37.06B 63.93B 4,404B 64.11B 439B 172B 2,220B 173B 169B 7,347B | 35.52B 48.26B 41.43B 38.79B 66.9B 4,609B 67.09B 459B 180B 2,323B 181B 177B 7,688B |
| Net income | 5.44B 7.39B 6.34B 5.94B 10.24B 705B 10.27B 70.29B 27.48B 356B 27.73B 27.13B 1,177B | 6.48B 8.81B 7.56B 7.08B 12.22B 842B 12.25B 83.85B 32.78B 424B 33.08B 32.37B 1,404B |
| Net Debt | 19.84B 26.96B 23.14B 21.67B 37.37B 2,575B 37.48B 257B 100B 1,298B 101B 99.03B 4,295B | 17.06B 23.18B 19.9B 18.63B 32.14B 2,214B 32.23B 221B 86.24B 1,116B 87.04B 85.16B 3,693B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-27 | GBX 1,852.00 | -2.50% | 3,067,637 |
| 26-08-26 | GBX 1,899.50 | -0.31% | 3,466,438 |
| 26-08-25 | GBX 1,905.50 | +0.79% | 4,599,767 |
| 26-08-24 | GBX 1,890.50 | -1.46% | 5,275,639 |
| 26-08-21 | GBX 1,918.50 | -0.10% | 4,820,018 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
